Home
Inbox
Search
Speaker
Vallerie V. McLaughlin
MD
Director of Pulmonary Hypertension Program, University of Michigan;University of Michigan;University of Michigan Medical Center
Bookmark
Session(s)
Baseline and Demographic Data on the First 250 Patients from SPHERE (UptraviĀ® [SelexiPag]:...
Tuesday, May 22
11:15 AM - 1:00 PM
Patient Characteristics and Treatment Patterns in the Largest Real-World Cohort of Pulmona...
Tuesday, May 22
11:15 AM - 1:00 PM
Transitions from Inhaled, Intravenous, Subcutaneous, or Oral Prostacyclins to Selexipag: I...
Tuesday, May 22
11:15 AM - 1:00 PM
Association of NT-proBNP and Long-Term Outcome in Pulmonary Arterial Hypertension (PAH): I...
Wednesday, May 23
1:30 PM - 3:30 PM
Ralinepag Plasma Levels Correlate with Improvements in Functional and Hemodynamic Paramete...
Wednesday, May 23
1:30 PM - 3:30 PM
Real-World Dosing and Titration of Selexipag in Patients with Pulmonary Arterial Hypertens...
Wednesday, May 23
1:30 PM - 3:30 PM
Home
Inbox
Search